GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (STU:A28A) » Definitions » Cyclically Adjusted PB Ratio

Affimed NV (STU:A28A) Cyclically Adjusted PB Ratio : 0.09 (As of May. 01, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Affimed NV Cyclically Adjusted PB Ratio?

As of today (2025-05-01), Affimed NV's current share price is €0.96. Affimed NV's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was €11.06. Affimed NV's Cyclically Adjusted PB Ratio for today is 0.09.

The historical rank and industry rank for Affimed NV's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:A28A' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.05   Med: 0.63   Max: 4.47
Current: 0.09

During the past years, Affimed NV's highest Cyclically Adjusted PB Ratio was 4.47. The lowest was 0.05. And the median was 0.63.

STU:A28A's Cyclically Adjusted PB Ratio is ranked better than
89.7% of 670 companies
in the Biotechnology industry
Industry Median: 1.47 vs STU:A28A: 0.09

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Affimed NV's adjusted book value per share data for the three months ended in Sep. 2024 was €1.049. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €11.06 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Affimed NV Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Affimed NV's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV Cyclically Adjusted PB Ratio Chart

Affimed NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1.91 0.72

Affimed NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.72 0.48 0.42 0.27

Competitive Comparison of Affimed NV's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Affimed NV's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affimed NV's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affimed NV's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Affimed NV's Cyclically Adjusted PB Ratio falls into.


;
;

Affimed NV Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Affimed NV's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.96/11.06
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Affimed NV's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Affimed NV's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book=Book Value per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=1.049/126.1978*126.1978
=1.049

Current CPI (Sep. 2024) = 126.1978.

Affimed NV Quarterly Data

Book Value per Share CPI Adj_Book
201412 13.259 99.543 16.809
201503 12.783 99.717 16.178
201506 25.168 100.417 31.630
201509 16.152 100.417 20.299
201512 20.227 99.717 25.599
201603 17.967 100.017 22.670
201606 15.803 100.717 19.801
201609 12.988 101.017 16.226
201612 11.651 101.217 14.527
201703 10.831 101.417 13.478
201706 9.134 102.117 11.288
201709 7.568 102.717 9.298
201712 6.749 102.617 8.300
201803 8.697 102.917 10.664
201806 7.562 104.017 9.175
201809 5.742 104.718 6.920
201812 6.428 104.217 7.784
201903 6.832 104.217 8.273
201906 5.260 105.718 6.279
201909 3.560 106.018 4.238
201912 5.071 105.818 6.048
202003 4.090 105.718 4.882
202006 4.794 106.618 5.674
202009 5.323 105.818 6.348
202012 7.325 105.518 8.761
202103 14.194 107.518 16.660
202106 12.602 108.486 14.659
202109 11.173 109.435 12.884
202112 11.015 110.384 12.593
202203 9.512 113.968 10.533
202206 12.911 115.760 14.075
202209 12.127 118.818 12.880
202212 10.239 119.345 10.827
202303 8.376 122.402 8.636
202306 6.624 123.140 6.788
202309 5.117 124.195 5.200
202312 3.854 123.773 3.930
202403 2.670 125.038 2.695
202406 1.831 125.882 1.836
202409 1.049 126.198 1.049

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Affimed NV  (STU:A28A) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Affimed NV Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Affimed NV's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Affimed NV Business Description

Industry
Traded in Other Exchanges
Address
Gottlieb-Daimler-Strabe 2, Mannheim, BW, DEU, 68165
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

Affimed NV Headlines

No Headlines